Advertisement
IMRN vs NONOF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRN is a Buy and NONOF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMRN’s FA Score shows that 1 FA rating(s) are green whileNONOF’s FA Score has 2 green FA rating(s).
- IMRN’s FA Score: 1 green, 4 red.
- NONOF’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMRN’s TA Score shows that 6 TA indicator(s) are bullish while NONOF’s TA Score has 5 bullish TA indicator(s).
- IMRN’s TA Score: 6 bullish, 2 bearish.
- NONOF’s TA Score: 5 bullish, 4 bearish.
Price Growth
IMRN (@Biotechnology) experienced а +6.63% price change this week, while NONOF (@Pharmaceuticals: Major) price change was -8.48% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.98%. For the same industry, the average monthly price growth was +9.31%, and the average quarterly price growth was +51.82%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.07%. For the same industry, the average monthly price growth was -0.30%, and the average quarterly price growth was +12.81%.
Reported Earning Dates
IMRN is expected to report earnings on Dec 03, 2025.
Industries' Descriptions
@Biotechnology (+3.98% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-1.07% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| IMRN | NONOF | IMRN / NONOF | |
| Capitalization | 13.4M | 261B | 0% |
| EBITDA | -7.35M | 154B | -0% |
| Gain YTD | 13.529 | -34.122 | -40% |
| P/E Ratio | N/A | 14.33 | - |
| Revenue | 6.54M | 312B | 0% |
| Total Cash | 7.74M | 18.9B | 0% |
| Total Debt | N/A | 99.3B | - |
IMRN | NONOF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 81 | |
SMR RATING 1..100 | 97 | 15 | |
PRICE GROWTH RATING 1..100 | 57 | 64 | |
P/E GROWTH RATING 1..100 | 100 | 98 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NONOF's Valuation (16) in the null industry is in the same range as IMRN (26) in the Biotechnology industry. This means that NONOF’s stock grew similarly to IMRN’s over the last 12 months.
NONOF's Profit vs Risk Rating (81) in the null industry is in the same range as IMRN (100) in the Biotechnology industry. This means that NONOF’s stock grew similarly to IMRN’s over the last 12 months.
NONOF's SMR Rating (15) in the null industry is significantly better than the same rating for IMRN (97) in the Biotechnology industry. This means that NONOF’s stock grew significantly faster than IMRN’s over the last 12 months.
IMRN's Price Growth Rating (57) in the Biotechnology industry is in the same range as NONOF (64) in the null industry. This means that IMRN’s stock grew similarly to NONOF’s over the last 12 months.
NONOF's P/E Growth Rating (98) in the null industry is in the same range as IMRN (100) in the Biotechnology industry. This means that NONOF’s stock grew similarly to IMRN’s over the last 12 months.
| IMRN | NONOF | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 69% | N/A |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 69% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 73% |
| Advances ODDS (%) | 2 days ago 74% | 9 days ago 76% |
| Declines ODDS (%) | 10 days ago 88% | 2 days ago 64% |
| BollingerBands ODDS (%) | N/A | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 77% |
Advertisement
IMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMRN has been closely correlated with LABFF. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if IMRN jumps, then LABFF could also see price increases.
| Ticker / NAME | Correlation To IMRN | 1D Price Change % | ||
|---|---|---|---|---|
| IMRN | 100% | +0.52% | ||
| LABFF - IMRN | 81% Closely correlated | N/A | ||
| MNMD - IMRN | 44% Loosely correlated | -0.51% | ||
| VYGR - IMRN | 26% Poorly correlated | -3.76% | ||
| CELZ - IMRN | 25% Poorly correlated | +4.50% | ||
| TCRX - IMRN | 24% Poorly correlated | -3.26% | ||
More | ||||
NONOF and
Correlation & Price change
A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.
| Ticker / NAME | Correlation To NONOF | 1D Price Change % | ||
|---|---|---|---|---|
| NONOF | 100% | -4.77% | ||
| NVO - NONOF | 70% Closely correlated | -4.60% | ||
| LABFF - NONOF | 23% Poorly correlated | N/A | ||
| IMRN - NONOF | 22% Poorly correlated | +0.52% | ||
| QSI - NONOF | 21% Poorly correlated | -6.21% | ||
| VRTX - NONOF | 21% Poorly correlated | +1.39% | ||
More | ||||